J. Wang , J. Fang , T. Shou , N. Yang , Q. Wang , J. Shi , K. Xiao , W. Zhuang , B. Wang , J. Hu , L. Liu , Y. Yu , Y. Zhang , X. Geng , Y. Zhong , C. Lowery , J. Chen , M.L. Johnson , L. Wang , Z. Chen
{"title":"25P: Durvalumab联合或不联合tremelimumab加化疗作为转移性NSCLC的一线治疗:来自III期POSEIDON扩展中国队列的结果","authors":"J. Wang , J. Fang , T. Shou , N. Yang , Q. Wang , J. Shi , K. Xiao , W. Zhuang , B. Wang , J. Hu , L. Liu , Y. Yu , Y. Zhang , X. Geng , Y. Zhong , C. Lowery , J. Chen , M.L. Johnson , L. Wang , Z. Chen","doi":"10.1016/S1556-0864(25)00220-5","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 3","pages":"Pages S27-S28"},"PeriodicalIF":21.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"25P: Durvalumab with or without tremelimumab plus chemotherapy as first-line treatment for metastatic NSCLC: Results from the phase III POSEIDON extended China cohort\",\"authors\":\"J. Wang , J. Fang , T. Shou , N. Yang , Q. Wang , J. Shi , K. Xiao , W. Zhuang , B. Wang , J. Hu , L. Liu , Y. Yu , Y. Zhang , X. Geng , Y. Zhong , C. Lowery , J. Chen , M.L. Johnson , L. Wang , Z. Chen\",\"doi\":\"10.1016/S1556-0864(25)00220-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":17515,\"journal\":{\"name\":\"Journal of Thoracic Oncology\",\"volume\":\"20 3\",\"pages\":\"Pages S27-S28\"},\"PeriodicalIF\":21.0000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Thoracic Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1556086425002205\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Thoracic Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1556086425002205","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
25P: Durvalumab with or without tremelimumab plus chemotherapy as first-line treatment for metastatic NSCLC: Results from the phase III POSEIDON extended China cohort
期刊介绍:
Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer,is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies.The readship includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology.